Suppr超能文献

源自Lewis肺癌的亚克隆在体内的生长由肿瘤微环境决定。

In vivo growth of subclones derived from Lewis lung carcinoma is determined by the tumor microenvironment.

作者信息

Xu Ben-Ling, Wang Xiao-Ming, Chen Guang-Yu, Yuan Peng, Han Lu, Qin Peng, Li Tie-Peng, You Hong-Qin, Zhang Cheng-Juan, Fu Xiao-Min, Yuan Long, Wang Zi-Bing, Gao Quan-Li

机构信息

Department of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital Zhengzhou 450008, Henan, P. R. China.

Department of General Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital Zhengzhou 450008, Henan, P. R. China.

出版信息

Am J Cancer Res. 2022 Nov 15;12(11):5255-5270. eCollection 2022.

Abstract

Heterogeneity is a fundamental feature of human tumors and plays a major role in drug resistance and disease progression. In the present study, we selected single-cell-derived cell lines (SCDCLs) derived from Lewis lung carcinoma (LLC1) cells to investigate tumorigenesis and heterogeneity. SCDCLs were generated using limiting dilution. Five SCDCLs were subcutaneously injected into wild-type C57BL/6N mice; however, they displayed significant differences in tumor growth. Subclone SCC1 grew the fastest in vivo, whereas it grew slower in vitro. The growth pattern of SCC2 was the opposite to that of SCC1. Genetic differences in these two subclones showed marked differences in cell adhesion and proliferation. Pathway enrichment results indicate that signal transduction and immune system responses were the most significantly altered functional categories in SCC2 cells compared to those in SCC1 cells in vitro. The number and activation of CD3 and CD8 T cells and NK cells in the tumor tissue of tumor-bearing mice inoculated with SCC2 were significantly higher, whereas those of myeloid cells were significantly lower, than those in the SCC1 and LLC1 groups. Our results suggest that the in vivo growth of two subclones derived from LLC1 was determined by the tumor microenvironment rather than their intrinsic proliferative cell characteristics.

摘要

异质性是人类肿瘤的一个基本特征,在耐药性和疾病进展中起主要作用。在本研究中,我们选择了源自Lewis肺癌(LLC1)细胞的单细胞衍生细胞系(SCDCLs)来研究肿瘤发生和异质性。SCDCLs通过有限稀释法产生。将五个SCDCLs皮下注射到野生型C57BL/6N小鼠体内;然而,它们在肿瘤生长方面表现出显著差异。亚克隆SCC1在体内生长最快,而在体外生长较慢。SCC2的生长模式与SCC1相反。这两个亚克隆的基因差异在细胞黏附和增殖方面表现出明显差异。通路富集结果表明,与体外SCC1细胞相比,SCC2细胞中信号转导和免疫系统反应是功能类别改变最显著的。接种SCC2的荷瘤小鼠肿瘤组织中CD3、CD8 T细胞和NK细胞的数量及活化程度明显高于SCC1和LLC1组,而髓样细胞的数量及活化程度则明显低于SCC1和LLC1组。我们的结果表明,源自LLC1的两个亚克隆的体内生长是由肿瘤微环境而非其内在的增殖细胞特性决定的。

相似文献

2
Subclone from CT26 resistant to anti-PD-1 therapy associated with increased expression of genes related to glucocorticoids.
Transl Oncol. 2024 Aug;46:102031. doi: 10.1016/j.tranon.2024.102031. Epub 2024 Jun 10.
4
6
Host CD39 Deficiency Affects Radiation-Induced Tumor Growth Delay and Aggravates Radiation-Induced Normal Tissue Toxicity.
Front Oncol. 2020 Oct 22;10:554883. doi: 10.3389/fonc.2020.554883. eCollection 2020.
7
Single-Cell-Derived Primary Rectal Carcinoma Cell Lines Reflect Intratumor Heterogeneity Associated with Treatment Response.
Clin Cancer Res. 2020 Jul 1;26(13):3468-3480. doi: 10.1158/1078-0432.CCR-19-1984. Epub 2020 Apr 6.
10
Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.
Cancer Res. 2014 Dec 15;74(24):7250-9. doi: 10.1158/0008-5472.CAN-13-3583. Epub 2014 Nov 6.

引用本文的文献

1
Intramuscular CMT-167 Tumors Produce a Mild Cachexia Phenotype in C57BL/6J Mice.
JCSM Commun. 2025 Jan-Jun;8(1). doi: 10.1002/rco2.117. Epub 2025 Feb 6.
3
Pulmonary lysyl oxidase expression and its role in seeding Lewis lung carcinoma cells.
Clin Exp Metastasis. 2024 Dec 23;42(1):7. doi: 10.1007/s10585-024-10325-y.
4
T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation.
Cancer Immunol Res. 2025 Feb 3;13(2):229-244. doi: 10.1158/2326-6066.CIR-24-0416.
7
Subclone from CT26 resistant to anti-PD-1 therapy associated with increased expression of genes related to glucocorticoids.
Transl Oncol. 2024 Aug;46:102031. doi: 10.1016/j.tranon.2024.102031. Epub 2024 Jun 10.
8
Exploring heterogeneity: a dive into preclinical models of cancer cachexia.
Am J Physiol Cell Physiol. 2024 Aug 1;327(2):C310-C328. doi: 10.1152/ajpcell.00317.2024. Epub 2024 Jun 10.

本文引用的文献

2
I-Labeled Monoclonal Antibody and Fragment for the Noninvasive Evaluation of Tumor PD-L1 Expression .
Mol Pharm. 2022 Oct 3;19(10):3551-3562. doi: 10.1021/acs.molpharmaceut.2c00084. Epub 2022 Mar 4.
3
Cancer statistics, 2022.
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
6
Toward personalized treatment approaches for non-small-cell lung cancer.
Nat Med. 2021 Aug;27(8):1345-1356. doi: 10.1038/s41591-021-01450-2. Epub 2021 Aug 12.
7
Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies.
Proc Natl Acad Sci U S A. 2021 Jul 27;118(30). doi: 10.1073/pnas.2025570118.
8
Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies.
Front Oncol. 2021 May 25;11:635007. doi: 10.3389/fonc.2021.635007. eCollection 2021.
10
Pathology and Classification of SCLC.
Cancers (Basel). 2021 Feb 16;13(4):820. doi: 10.3390/cancers13040820.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验